On May 4, Axinn partners Ted Mathias and Stacie Ropka participated in a video interview with The Center for Biosimilars. They discussed the overall pushback to the Affordable Care Act (ACA) and what that means for the Biologics Price Competition and Innovation Act (BPCIA).
Axinn Patent Attorneys Talk ACA Pushback and the BPCIA
May 4, 2020
The Center for Biosimilars